Moderna, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
MRNA$269.00+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in millions, except per share data)
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,195 | $2,595 |
| Investments | 3,976 | 3,204 |
| Accounts receivable, net | 1,367 | 184 |
| Inventory | 313 | 153 |
| Prepaid expenses and other current assets | 493 | 408 |
| Total current assets | 7,344 | 6,544 |
| Investments, non-current | 2,805 | 2,336 |
| Property, plant and equipment, net | 2,036 | 2,134 |
| Right-of-use assets, operating leases | 687 | 719 |
| Other non-current assets | 596 | 605 |
| Total assets | $13,468 | $12,338 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $259 | $317 |
| Accrued liabilities | 1,395 | 1,386 |
| Deferred revenue | 268 | 99 |
| Other current liabilities | 106 | 185 |
| Total current liabilities | 2,028 | 1,987 |
| Deferred revenue, non-current | 139 | 153 |
| Operating lease liabilities, non-current | 630 | 653 |
| Financing lease liabilities, non-current | — | 20 |
| Long-term debt | 591 | 590 |
| Convertible notes | 2,958 | — |
| Other non-current liabilities | 285 | 285 |
| Total liabilities | 6,631 | 3,688 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.0001; 162 shares authorized as of September 30, 2026 and December 31, 2025; no shares issued or outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Common stock, par value $0.0001; 1,600 shares authorized as of September 30, 2026 and December 31, 2025; 404 and 394 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 1,569 | 1,382 |
| Accumulated other comprehensive income | 8 | 45 |
| Retained earnings | 5,260 | 7,223 |
| Total stockholders’ equity | 6,837 | 8,650 |
| Total liabilities and stockholders’ equity | $13,468 | $12,338 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.